Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its ...

In atopic dermatitis, the first interleukin-22 inhibitor to reach late clinical trials is showing uncommonly broad suppression of biomarkers associated with disease activity.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that it intends to develop its ...

Schematic of the early-stage characteristics of house dust mites-induced bronchial fibroblasts, which are characterized by ...

The IL-6 receptor antagonist market presents significant opportunities in underexplored areas like thyroid eye disease and atherosclerotic cardiovascular disease (ASCVD). Recent acquisitions and ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

Presented in an oral session at the 67th American Society of Hematology Annual Meeting & Exposition ...

By Dengyuemed International Business Department  November 28 — The National Medical Products Administration (NMPA) has approved the marketing of picankibart injection, an innovative IL-23p19–targeting ...

Tiziana Life Sciences considers the antibody, known as TZLS-501, to have potential to operate as a standalone business and intends to proceed with steps for a publicly-listed immunology-focused ...

Ischemic stroke is a complex cerebrovascular disorder characterized by highly unpredictable outcomes influenced by patient-specific variables, including age, stroke severity, and preventable ...